ATE410161T1 - 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen - Google Patents
4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungenInfo
- Publication number
- ATE410161T1 ATE410161T1 AT04750891T AT04750891T ATE410161T1 AT E410161 T1 ATE410161 T1 AT E410161T1 AT 04750891 T AT04750891 T AT 04750891T AT 04750891 T AT04750891 T AT 04750891T AT E410161 T1 ATE410161 T1 AT E410161T1
- Authority
- AT
- Austria
- Prior art keywords
- carboxyromide
- bradykinin
- benzoylamino
- pyrazole
- bromo
- Prior art date
Links
- 229940104754 Bradykinin B1 receptor antagonist Drugs 0.000 title 1
- 239000003144 bradykinin B1 receptor antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46769503P | 2003-05-02 | 2003-05-02 | |
US53954604P | 2004-01-27 | 2004-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE410161T1 true ATE410161T1 (de) | 2008-10-15 |
Family
ID=33436740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04750891T ATE410161T1 (de) | 2003-05-02 | 2004-04-30 | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
Country Status (11)
Country | Link |
---|---|
US (2) | US7432379B2 (de) |
EP (1) | EP1633348B1 (de) |
JP (1) | JP2006526015A (de) |
AR (1) | AR044163A1 (de) |
AT (1) | ATE410161T1 (de) |
CA (1) | CA2524269A1 (de) |
DE (1) | DE602004016992D1 (de) |
ES (1) | ES2314418T3 (de) |
PE (1) | PE20050525A1 (de) |
TW (1) | TW200509910A (de) |
WO (1) | WO2004098589A1 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1635821B1 (de) * | 2003-05-02 | 2009-07-08 | Elan Pharmaceuticals, Inc. | 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3-carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen |
CA2524274A1 (en) * | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
JP2006526015A (ja) * | 2003-05-02 | 2006-11-16 | エラン ファーマシューティカルズ,インコーポレイテッド | 炎症疾患治療のためのブラジキニンb1受容体アンタゴニストとしての4−ブロモ−5−(2−クロロ−ベンゾイルアミノ)−1h−ピラゾール−3−カルボン酸アミド誘導体および関連化合物 |
US20060247152A1 (en) * | 2005-05-02 | 2006-11-02 | Russ Lebovitz | Substituted fullerenes and their use as inhibitors of cell death |
NZ551603A (en) | 2004-06-24 | 2010-11-26 | Incyte Corp | N-substituted piperidines and their use as pharmaceuticals |
PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
WO2006071775A2 (en) * | 2004-12-29 | 2006-07-06 | Elan Pharmaceuticals, Inc. | Novel compounds useful for bradykinin b1 receptor antagonism |
JP2008537953A (ja) * | 2005-04-15 | 2008-10-02 | エラン ファーマシューティカルズ,インコーポレイテッド | ブラジキニンb1受容体拮抗作用に有用な新規化合物 |
AU2006250354A1 (en) * | 2005-05-23 | 2006-11-30 | Japan Tobacco Inc. | Pyrazole compound and therapeutic agent for diabetes comprising the same |
JP2007191461A (ja) * | 2005-05-23 | 2007-08-02 | Japan Tobacco Inc | ピラゾール化合物及びそれらピラゾール化合物を含んでなる糖尿病治療薬 |
US20100016374A1 (en) * | 2006-04-05 | 2010-01-21 | Steven Coulton | Compounds Which Inhibit the Glycine Transporter and Uses Thereof |
WO2008062739A1 (fr) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles et leur utilisation en tant que médicaments |
WO2009041447A1 (ja) | 2007-09-28 | 2009-04-02 | Takeda Pharmaceutical Company Limited | 5員複素環化合物 |
CN101965177A (zh) | 2008-02-08 | 2011-02-02 | 株式会社资生堂 | 美白剂和皮肤外用剂 |
WO2009154208A1 (ja) * | 2008-06-17 | 2009-12-23 | 日産化学工業株式会社 | 液晶配向処理剤及びそれを用いた液晶表示素子、並びに新規なジアミン |
UA107457C2 (uk) | 2009-03-26 | 2015-01-12 | Такеда Фармасьютікал Компані Лімітед | Похідні піразолу |
KR20120027111A (ko) * | 2009-03-31 | 2012-03-21 | 제리아 신야쿠 고교 가부시키 가이샤 | 1, 5-벤조디아제핀 유도체의 제조법 |
KR102113960B1 (ko) | 2010-03-30 | 2020-05-21 | 베르선 코포레이션 | 트롬빈 억제제로서의 다중치환된 방향족 화합물 |
US8859606B2 (en) | 2010-07-01 | 2014-10-14 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
US9289365B2 (en) * | 2011-10-24 | 2016-03-22 | Avon Products, Inc. | Compositions and methods for stimulating collagen synthesis in the skin |
US20140171404A1 (en) | 2012-12-19 | 2014-06-19 | Novartis Ag | Autotaxin inhibitors |
US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
TWI648273B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類(三) |
ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
EP2968297B1 (de) | 2013-03-15 | 2018-09-26 | Verseon Corporation | Multisubstituierte aromatische verbindungen als serinproteaseinhibitoren |
US9771351B2 (en) | 2013-07-29 | 2017-09-26 | Kyowa Hakko Kirin Co., Ltd. | Wnt signaling inhibitor |
EP3131891A1 (de) * | 2014-04-15 | 2017-02-22 | Pfizer Inc. | Tropomysin-verwandte kinaseinhibitoren mit einer 1h-pyrazol- sowie pyrimidineinheit |
EP3140298A1 (de) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-assoziierte kinaseinhibitoren |
CN106573006A (zh) * | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
WO2016044662A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
WO2016105448A1 (en) * | 2014-12-22 | 2016-06-30 | Darryl Rideout | Imidazoline receptor type 1 ligands for use as therapeutics |
WO2016138532A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
US10787462B2 (en) * | 2015-10-23 | 2020-09-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
KR20180114910A (ko) | 2016-02-05 | 2018-10-19 | 데날리 테라퓨틱스 인크. | 수용체-상호작용 단백질 키나제 1의 억제제 |
CN110023313B (zh) | 2016-12-02 | 2022-10-25 | 豪夫迈·罗氏有限公司 | 二环酰胺化合物及其使用方法 |
WO2018107060A1 (en) | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
RS65308B1 (sr) | 2017-07-14 | 2024-04-30 | Hoffmann La Roche | Biciklična ketonska jedinjenja i postupci za njihovu upotrebu |
SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
GB201911944D0 (en) * | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
GB201915932D0 (en) * | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
CN111423377B (zh) * | 2020-05-12 | 2021-06-01 | 中国药科大学 | 5-氨基-1h-吡唑衍生物、制备方法及医药用途 |
US11999750B2 (en) | 2022-01-12 | 2024-06-04 | Denali Therapeutics Inc. | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide |
WO2023164538A1 (en) * | 2022-02-23 | 2023-08-31 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
WO2023164537A1 (en) * | 2022-02-23 | 2023-08-31 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
WO2023164536A1 (en) * | 2022-02-23 | 2023-08-31 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654275A (en) | 1969-10-15 | 1972-04-04 | Pfizer & Co C | Quinoxalinecarboxamide antiinflammatory agents |
JPS49100080A (de) | 1973-02-01 | 1974-09-20 | ||
DE3421386A1 (de) * | 1984-06-08 | 1985-12-12 | A. Nattermann & Cie GmbH, 5000 Köln | Neue n-pyrazolyl-1,2-benzothiazin-3-carboxamide und diese enthaltende pharmazeutische praeparate |
JPH03168743A (ja) | 1989-11-29 | 1991-07-22 | Konica Corp | イミダゾール系染料 |
GB9416005D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Peptidic compounds analogous to distamycin a and process for their preparation |
WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
US6433185B1 (en) * | 1996-01-11 | 2002-08-13 | Sanofi-Synthelabo | N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them |
GB2310207A (en) | 1996-02-15 | 1997-08-20 | Pharmacia Spa | Antiviral ureido derivatives of substituted heterocyclic compounds |
WO1998011101A2 (en) | 1996-09-12 | 1998-03-19 | Cancer Research Campaign Technology Limited | Condensed n-aclyindoles as antitumor agents |
IL129820A0 (en) | 1996-12-23 | 2000-02-29 | Elan Pharm Inc | Cycloalkyl lactam lactone and related compounds as beta-amyloid peptide release inhibitors |
KR19980057929U (ko) * | 1997-02-14 | 1998-10-26 | 배순훈 | 세탁기의 펄세이터 |
AU1711499A (en) | 1997-12-04 | 1999-06-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds or inhibition of inflammation |
DE19854081A1 (de) | 1998-11-24 | 2000-05-25 | Bayer Ag | Substituierte N-Pyrazolyl-phenoxynicotinsäure-(thio)amide |
FR2790260B1 (fr) * | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
JP2003505384A (ja) | 1999-07-15 | 2003-02-12 | ファーマコピーア,インコーポレーティッド | ブラジキニンb1受容体アンタゴニスト |
EP1268472B1 (de) * | 2000-02-07 | 2004-10-13 | Bristol-Myers Squibb Company | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen |
AU2000254308A1 (en) | 2000-05-17 | 2001-11-26 | Sk Chemicals Co., Ltd. | Pyrazolopyrimidinone derivatives, process for their preparation and their use |
IL153119A0 (en) * | 2000-06-27 | 2003-06-24 | Genelabs Tech Inc | Novel compounds possessing antibacterial, antifungal or antitumor activity |
GB0016447D0 (en) * | 2000-07-04 | 2000-08-23 | Pharmacia & Upjohn Spa | Process for preparing distamycin derivatives |
GB0016787D0 (en) * | 2000-07-07 | 2000-08-30 | Pfizer Ltd | Compounds useful in therapy |
JP2002220376A (ja) * | 2000-07-25 | 2002-08-09 | Sankyo Co Ltd | 5−(m−シアノベンジルアミノ)ピラゾール誘導体 |
AU2001272781A1 (en) | 2000-07-25 | 2002-02-05 | Sankyo Company Limited | 5-(m-cyanobenzylamino)pyrazole derivatives |
IT1318696B1 (it) | 2000-09-15 | 2003-08-27 | Pharmacia & Upjohn Spa | Coniugati di glutatione con derivati della distamicina ad attivita'antitumorale. |
FR2822827B1 (fr) | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
WO2002099388A2 (en) | 2001-06-07 | 2002-12-12 | Merck & Co., Inc. | Benzodiazepine bradykinin antagonists |
DE10134721A1 (de) | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
BR0207583A (pt) | 2001-12-26 | 2004-04-27 | Genelabs Tech Inc | Derivados de poliamida possuindo atividade antibacteriana, antifungo ou antitumor |
US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
DE10221052A1 (de) | 2002-05-10 | 2003-12-04 | Transmit Technologietransfer | Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten |
AU2003263518A1 (en) | 2002-10-09 | 2004-05-04 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
JP2006526015A (ja) | 2003-05-02 | 2006-11-16 | エラン ファーマシューティカルズ,インコーポレイテッド | 炎症疾患治療のためのブラジキニンb1受容体アンタゴニストとしての4−ブロモ−5−(2−クロロ−ベンゾイルアミノ)−1h−ピラゾール−3−カルボン酸アミド誘導体および関連化合物 |
CA2524274A1 (en) * | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
EP1635821B1 (de) * | 2003-05-02 | 2009-07-08 | Elan Pharmaceuticals, Inc. | 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3-carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen |
-
2004
- 2004-04-30 JP JP2006513431A patent/JP2006526015A/ja active Pending
- 2004-04-30 PE PE2004000439A patent/PE20050525A1/es not_active Application Discontinuation
- 2004-04-30 ES ES04750891T patent/ES2314418T3/es not_active Expired - Lifetime
- 2004-04-30 TW TW093112310A patent/TW200509910A/zh unknown
- 2004-04-30 EP EP04750891A patent/EP1633348B1/de not_active Expired - Lifetime
- 2004-04-30 CA CA002524269A patent/CA2524269A1/en not_active Abandoned
- 2004-04-30 DE DE602004016992T patent/DE602004016992D1/de not_active Expired - Fee Related
- 2004-04-30 US US10/837,231 patent/US7432379B2/en not_active Expired - Fee Related
- 2004-04-30 WO PCT/US2004/013219 patent/WO2004098589A1/en active Application Filing
- 2004-04-30 US US10/555,519 patent/US7417152B2/en not_active Expired - Fee Related
- 2004-04-30 AT AT04750891T patent/ATE410161T1/de not_active IP Right Cessation
- 2004-05-03 AR ARP040101509A patent/AR044163A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2006526015A (ja) | 2006-11-16 |
TW200509910A (en) | 2005-03-16 |
US20060281733A1 (en) | 2006-12-14 |
US7432379B2 (en) | 2008-10-07 |
EP1633348A1 (de) | 2006-03-15 |
WO2004098589A1 (en) | 2004-11-18 |
DE602004016992D1 (de) | 2008-11-20 |
CA2524269A1 (en) | 2004-11-18 |
EP1633348B1 (de) | 2008-10-08 |
US7417152B2 (en) | 2008-08-26 |
PE20050525A1 (es) | 2005-09-08 |
WO2004098589A8 (en) | 2005-12-08 |
AR044163A1 (es) | 2005-08-24 |
US20050020659A1 (en) | 2005-01-27 |
ES2314418T3 (es) | 2009-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE410161T1 (de) | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen | |
ATE472327T1 (de) | Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
ATE428694T1 (de) | N-ä1h-indol-5-ylünaphthalin-1-sulphonamid- derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems | |
ATE371451T1 (de) | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie | |
DE602005023172D1 (de) | Hydantoinderivate zur behandlung von entzündlichen erkrankungen | |
DE602004010419D1 (de) | Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
ATE499370T1 (de) | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen | |
ATE369333T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
ATE331512T1 (de) | Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie | |
ATE524479T1 (de) | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren | |
ATE375977T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
DE602005015577D1 (de) | Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
DE60328690D1 (de) | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen | |
ATE529427T1 (de) | Ä1h-indol-5-yl)-heteroaryloxyü-(1-aza-bicyclo- ä3.3.1ü-nonane als cholinergische liganden des n- achr zur behandlung psychotischer und neurodegenerativer leiden | |
DE60221569D1 (de) | Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen | |
DE602005026984D1 (de) | Chinolin-derivate zur behandlung von latenter tuberkulose | |
DE502005003904D1 (de) | Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten | |
ATE437861T1 (de) | 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen | |
ATE534633T1 (de) | Indazolderivate zur behandlung von hsp90- induzierten krankheiten | |
ATE505468T1 (de) | N-gebundene heterocyclische antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
ATE504580T1 (de) | Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit | |
DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
DE602004003952D1 (de) | Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders | |
DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |